Last reviewed · How we verify
DERACOXIB
Deracoxib is a small molecule drug that targets prostaglandin G/H synthase 2, a key enzyme involved in inflammation. It is used to treat pain and inflammation in dogs. The commercial status of deracoxib is patented, and it is currently owned by Zoetis. Deracoxib is not approved for human use. It is a nonsteroidal anti-inflammatory drug (NSAID) that works by inhibiting the production of prostaglandins, which are hormone-like substances that cause pain and inflammation.
At a glance
| Generic name | DERACOXIB |
|---|---|
| Target | Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2, Cyclooxygenase 2; Prostaglandin G/H synthase-2; Uncharacterized protein |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DERACOXIB CI brief — competitive landscape report
- DERACOXIB updates RSS · CI watch RSS